Summary

Eligibility
for people ages 30 years and up (full criteria)
Location
at UC Davis UC Irvine UCLA UCSD
Dates
study started
completion around
Principal Investigator
by Kwan Ng (ucdavis)

Description

Summary

The primary goal of the trial is to determine if the experimental arms (rivaroxaban or ticagrelor or both) are superior to the clopidogrel arm for lowering the 1-year rate of ischemic stroke, intracerebral hemorrhage, or vascular death.

Official Title

Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis (CAPTIVA)

Details

The proposed study is relevant to public health because narrowing of brain arteries is one of the most common causes of stroke worldwide. Compelling evidence suggests novel antithrombotic medications could reduce the rate of stroke in patients with narrowed brain arteries. The proposed study will directly compare novel antithrombotic medications to standard care antiplatelet medications for preventing stroke and death from vascular causes in patients with narrowed brain arteries.

Keywords

Intracranial Arteriosclerosis, Stroke, Arteriosclerosis, Aspirin, Rivaroxaban, Clopidogrel, Ticagrelor, Ticagrelor + Aspirin, Rivaroxaban + Aspirin, Clopidogrel + Aspirin, Risk Factor Management

Eligibility

Locations

Lead Scientist at University of California Health

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of Florida
ID
NCT05047172
Phase
Phase 3 research study
Study Type
Interventional
Participants
Expecting 1683 study participants
Last Updated